Guardant Health, Inc.

NASDAQ:GH

Medical - Diagnostics & Research

Healthcare
$145.14 +2.07%

+$2.67 today

Market cap
$19.64B
Beta
1.62
P/E (TTM)
-39.9
EPS (TTM)
-$3.30
52W Low $40.35High $135.00

Volume 1.50M

Average 2.21M

GH EBITDA Margin

EBITDA as a percentage of revenue.

Guardant Health, Inc.NASDAQ: GH

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin holds steady near -31.2%

EBITDA Margin was -31.2% in Q3 FY2026, down 0.2 pp from a year earlier. On a trailing-twelve-month basis it was -34.5%, up 4.7 pp year over year. Over 3 fiscal years it widened by 98.7 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 19 analysts of -26.9% for the fiscal year ending Dec 2026, up from -38.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-31.2%+1.4 pp QoQ
Last fiscal yearDec 2025
-38.1%+14.7 pp YoY
LTMSep 2026
-34.5%+4.7 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-0.2 pp+18.6 pp+18.8 pp
1 year+14.7 pp+11.2 pp-3.5 pp
3 years+98.7 pp+39.2 pp-59.5 pp
5 years+46.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-38.1%
Year-over-year change
+14.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How GH compares with its peers on the latest reported figures

  • GH's LTM Sep 2026 EBITDA Margin of -34.5% is the 7th highest of the 10 companies compared; the peer median is -18.3%.
  • Its year-over-year change of +4.7 pp is the 5th highest of 10, against a peer median of +4.2 pp.
  • Over three fiscal years its change of +98.7 pp compares with a peer median of +45.9 pp.
GH Competitors Peer median
EBITDA Margin for GH and competitors
Company Period LTM level YoY 3-year change
BLLNBillionToOne, Inc.LTM Jun 202612.6% +21.8 pp—
NEONeoGenomics, Inc.LTM Jun 20261.7% +5.8 pp+10.8 pp
CSTLCastle Biosciences, Inc.LTM Mar 2026-0.2% -12.0 pp+45.9 pp
NTRANatera, Inc.LTM Jun 2026-6.6% +4.2 pp+53.9 pp
FLGTFulgent Genetics, Inc.LTM Mar 2026-18.3% -9.7 pp-49.4 pp
BDSXBiodesix, Inc.LTM Mar 2026-19.1% +17.8 pp+110.1 pp
GHGuardant Health, Inc.LTM Sep 2026-34.5% +4.7 pp+98.7 pp
MYGNMyriad Genetics, Inc.LTM Mar 2026-40.3% -32.6 pp-27.6 pp
PSNLPersonalis, Inc.LTM Mar 2026-132.6% -47.0 pp—
GRALGRAIL, Inc.LTM Jun 2026-226.4% +86.1 pp+801.0 pp
Peer median (excluding GH) -18.3%+4.2 pp+45.9 pp

Competitors are the stored peer set for GH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue373.65M449.54M563.95M739.02M982.02M
Cost of Revenue122.91M156.33M227.05M289.8M349.01M
Gross Profit250.74M293.21M336.9M449.22M633.01M
Gross Margin67.1%65.2%59.7%60.8%64.5%
Research & Development263.22M373.81M367.19M347.75M364.19M
Selling, General & Admin398.52M463.78M451.03M545.06M706.07M
Operating Expenses661.74M837.59M901.62M892.81M1.07B
Depreciation & Amortization22.27M35.96M42.88M42.39M39.74M
EBITDA(359.62M)(614.91M)(433.31M)(390.12M)(373.91M)
EBITDA Margin-96.2%-136.8%-76.8%-52.8%-38.1%
Operating Income(411M)(544.38M)(564.73M)(443.59M)(437.25M)
Operating Margin-110.0%-121.1%-100.1%-60.0%-44.5%
Interest Income3.93M6.07M35.37M53.69M34.1M
Interest Expense2.58M2.58M2.58M2.58M3.9M
Other Income / Expenses26.53M(109.07M)85.96M8.51M19.71M
Income Before Tax(384.47M)(653.45M)(478.76M)(435.09M)(417.54M)
Pre-Tax Margin-102.9%-145.4%-84.9%-58.9%-42.5%
Income Tax Expense300K1.14M685K1.28M(1.26M)
Net Income(405.67M)(654.59M)(479.45M)(436.37M)(416.28M)
Net Margin-108.6%-145.6%-85.0%-59.0%-42.4%
EPS (Basic)(4.00)(6.41)(4.28)(3.56)(3.32)
EPS (Diluted)(4.00)(6.41)(4.28)(3.56)(3.32)
Weighted Avg Shares101.31M102.18M111.99M122.75M125.37M
Weighted Avg Shares (Diluted)101.31M102.18M111.99M122.75M125.37M

Guardant Health, Inc.

NASDAQ:GH

Intrinsic Alpha fair value

Locked

Current Price

$145.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.